Peripheral blood CD45RO+T cells is a predictor of the effectiveness of neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Cell Separation
Chemoradiotherapy, Adjuvant
/ methods
Colonoscopy
Cyclophosphamide
/ therapeutic use
Disease-Free Survival
Doxorubicin
/ therapeutic use
Flow Cytometry
Follow-Up Studies
Humans
Leukocyte Common Antigens
/ metabolism
Lymphocyte Count
Male
Middle Aged
Neoadjuvant Therapy
/ methods
Neoplasm Recurrence, Local
/ diagnosis
Neoplasm Staging
Oxaliplatin
/ therapeutic use
Prednisone
/ therapeutic use
Preoperative Period
Proctectomy
Prognosis
Radiotherapy, Intensity-Modulated
Rectal Neoplasms
/ blood
Rectum
/ diagnostic imaging
Retrospective Studies
Survival Rate
T-Lymphocyte Subsets
/ immunology
Vindesine
/ therapeutic use
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
25 Jun 2021
25 Jun 2021
Historique:
received:
06
09
2020
accepted:
17
05
2021
entrez:
23
6
2021
pubmed:
24
6
2021
medline:
2
7
2021
Statut:
ppublish
Résumé
To investigate the relationship between the changes in circulating CD45RO+T lymphocyte subsets following neoadjuvant therapy for rectal cancer in patients with locally advanced rectal cancer.The clinicopathological data of 185 patients with rectal cancer who received neoadjuvant therapy in the General Surgery Department of Beijing Chaoyang Hospital affiliated to Capital Medical University from June 2015 to June 2017 were analyzed. Venous blood samples were collected 1 week before neoadjuvant therapy and 1 week before surgery, and the expression of CD45RO+T was detected by flow cytometry. The receiver operating characteristic curve analysis was used to determine the optimal cut-off point of CD45RO+ratio. Log-rank test and multivariate Cox regression were used to analyze the overall survival rate (OS) and disease-free survival rate (DFS) associated with CD45RO+ratio.Circulating CD45RO+ratio of 1.07 was determined as the optimal cut-off point and CD45RO+ratio-high was associated with lower tumor regression grade grading (P = .031), T stage (P = .001), and tumor node metastasis (TNM) stage (P = .012). The 3-year DFS and OS rate in the CD45RO+ratio-high group was significantly higher than that in the CD45RO+ratio-low group (89.2% vs 60.1%, P<.001; 94.4% vs 73.2%, P<.001). The multivariate Cox analysis revealed that elevated CD45RO+ratio was an independent factor for better DFS (OR, 0.339; 95% CI, 0.153-0.752; P = .008) and OS (OR, 0.244; 95% CI,0.082-0.726; P = .011).Circulating CD45RO+ratio could predict the tumor regression grade of neoadjuvant therapy for rectal cancer, as well as long-term prognosis. These findings could be used to stratify patients and develop alternative strategies for adjuvant therapy.
Identifiants
pubmed: 34160385
doi: 10.1097/MD.0000000000026214
pii: 00005792-202106250-00008
pmc: PMC8238272
doi:
Substances chimiques
Oxaliplatin
04ZR38536J
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Leukocyte Common Antigens
EC 3.1.3.48
Vindesine
RSA8KO39WH
Prednisone
VB0R961HZT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e26214Informations de copyright
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:07–34.
Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009;373:811–20.
Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012;30:1926–33.
Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009;10:718–26.
Ma Y, Kepp O, Ghiringhelli F, et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol 2010;22:113–24.
Oh SY, Heo J, Noh OK, et al. Absolute lymphocyte count in preoperative chemoradiotherapy for rectal cancer: changes over time and prognostic Significance. Technol Cancer Res Treat 2018;17:1533033818780065.
Kitayama J, Yasuda K, Kawai K, et al. Circulating lymphocyte is an important determinant of the effectiveness of preoperative radiotherapy in advanced rectal cancer. BMC Cancer 2011;11:64.
Vallard A, Garcia MA, Diao P, et al. Outcomes prediction in pre-operative radiotherapy locally advanced rectal cancer: leucocyte assessment as immune biomarker. Oncotarget 2018;9:22368–82.
Deng YX, Lin JZ, Peng JH, et al. Lymphocyte-to-monocyte ratio before chemoradiotherapy represents a prognostic predictor for locally advanced rectal cancer. Onco Targets Ther 2017;10:5575–83.
Tada N, Kawai K, Tsuno NH, et al. Prediction of the preoperative chemoradiotherapy response for rectal cancer by peripheral blood lymphocyte subsets. World J Surg Oncol 2015;13:30.
Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol 2014;14:24–35.
Amsen D, van Gisbergen K, Hombrink P, et al. Tissue-resident memory T cells at the center of immunity to solid tumors. Nat Immunol 2018;19:538–46.
Wang L, Zhai ZW, Ji DB, et al. Prognostic value of CD45RO (+) tumor-infiltrating lymphocytes for locally advanced rectal cancer following 30 Gy/10f neoadjuvant radiotherapy. Int J Colorectal Dis 2015;30:753–60.
Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–55.
Ryan R, Gibbons D, Hyland JM, et al. Pathological response following long course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 2005;47:141–6.
Demaria S, Formenti SC. Role of T lymphocytes in tumor response to radiotherapy. Front in Oncol 2012;2:95.
Hu G, Wang S. Tumor-infiltrating CD45RO (+) memory T lymphocytes predict favorable clinical outcome in solid tumors. Sci Rep 2017;7:10376.
Ellis GI, Reneer MC, Velez-Ortega AC, McCool A, Martí F, et al. Generation of induced regulatory T cells from primary human naive and memory T cells. J Vis Exp 2012;3738.
Hsu M, Sedighim S, Wang T, et al. TCR sequencing can identify and track glioma-infiltrating T cells after DC vaccination. Cancer Immunol Res 2016;4:412–8.
Yang P, Ma J, Yang X, et al. Peripheral CD4+ naïve/memory ratio is an independent predictor of survival in non-small cell lung cancer. Oncotarget 2017;8:83650–9.
Hang J, Huang J, Zhou S, et al. The clinical implication of CD45RA+ naïve T cells and CD45RO+ memory T cells in advanced pancreatic cancer: a proxy for tumor biology and outcome prediction. Cancer Med 2019;8:1326–35.
Chen L, Zhang F, Sheng XG, et al. Peripheral platelet/lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil: lymphocyte. Medicine (Baltimore) 2016;95:e4381.
Yamada S, Fujii T, Yabusaki N, et al. Clinical implication of inflammation-based prognostic score in pancreatic cancer: Glasgow prognostic score is the most reliable parameter. Medicine (Baltimore) 2016;95:e3582.
Wu Z, Zhang J, Cai Y, et al. Reduction of circulating lymphocyte count is a predictor of good tumor response after neoadjuvant treatment for rectal cancer. Medicine (Baltimore) 2018;97:e11435.
Demaria S, Golden EB, Formenti SC. Role of local radiation therapy in cancer immunotherapy. JAMA Oncol 2015;1:1325–32.
Zitvogel L, Galluzzi L, Smyth MJ, et al. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013;39:74–88.
Apetoh L, Locher C, Ghiringhelli F, et al. Harnessing dendritic cells in cancer. Semin Immunol 2011;23:42–9.
Scheper W, Kelderman S, Fanchi LF, et al. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med 2019;25:89–94.